(PharmaNewsWire.Com, November 11, 2019 ) Market Overview • Osteoporosis is a skeletal disorder characterized by gradual weakening of the bones which occurs as a result of hormonal fluctuations, vitamin deficiency, or aging, and leads to excessive loss of bone mass, bone fragility, increased risk of fractures. It can be classified as primary osteoporosis and secondary osteoporosis. • Secondary osteoporosis develops as a result of another medical condition. The global osteoporosis drug market in 2016 was USD 8 billion with a patient pool of over 200 million worldwide. • Osteoporosis is more prevalent among women, particularly after the age of 50. Men are also affected by the disorder. The condition affects one in three women and one in five men over 50 years of age. • Worldwide, osteoporosis causes more than 8.9 million fractures annually. By 2050, the global incidence of hip fracture in men is projected to increase by 310% and 240% in women.
Market Growth • The most important driver of growth in the global osteoporosis market will be the shift from current therapies to the ones with enhanced efficacy, convenience, and safety profiles. • This is expected to expand the market. Increased patient and physician awareness will lead to screening and hence, earlier disease diagnosis and treatment, thereby further driving the market. • However, increased uptake of generic drugs owing to the patent expiration of blockbuster drugs will hinder market growth. Poor patient compliance due to side-effects and complications associated with the administration of osteoporosis drugs is another crucial factor that acts as a barrier to market growth.
Market Segmentation • Based on the treatment type, the global osteoporosis market is categorized into six different drug classes. • These are bisphosphonates, SERMs, anti-RANKL monoclonal antibody, strontium salt, Parathyroid Hormone Therapy (PTH), and calcitonin-salmon products. • Among these drug classes, bisphosphonates are considered as the gold standard of treatment and dominated the market until they lost their patent protection in 2013. New drug classes such as RANKL and PTH will dominate the market regarding sales. • Geographically, the global osteoporosis drugs market has been segmented into four regions: North America, Europe, Asia-Pacific and Rest of the World (RoW). • In the North America region, the US represents the largest market for osteoporosis with almost 44 million people aged 50 and above in the US living with either osteoporosis or low bone mass. • This 44 million represents 55% of the population aged 50 years and older. As a result, an estimated 2 million fractures are attributed to osteoporosis each year. This number is expected to increase to 3 million by the year 2025. North America is followed by Europe, and Asia-Pacific region. • The report includes profiles of major players dominating the global osteoporosis market, such as Amgen, Eli Lilly, Pfizer, Merck, Novartis, GlaxoSmithKline, Roche, Teva Pharmaceuticals, Novo Nordisk and so on.
Application-based Analysis The scope of the Osteoporosis Market Report By Drug Class • Bisphosphonates • RANKL Antagonist • Selective Estrogen Receptor Modulators • Parathyroid Hormone Analog • Strontium • Calcitonin • Anti-Sclerostin • Cathepsin K Inhibitor By Product Type • Branded • Generics By Region • Asia Pacific (China, Japan, India, Australia, Rest of Asia Pacific) • Europe (Germany, France, The UK, Italy, Spain, Rest of Europe) • North America (The USA, Canada, Mexico) • South America (Brazil, Argentina, Rest of South America) • Rest of the World.
About Us DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within a span of less than a year we have secured more than 100 unique customers from established organizations all over the world. For more information: Sai Kiran Sales Manager at Data M Intelligence Email: info@datamintelligence.com Tel: +1 877 441 4866 Website: www.datamintelligence.com
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
